An abrupt increase in metastatic growth as a consequence of the removal of primary
tumors suggests that the concomitant resistance (CR) phenomenon might occur in human
cancer. CR occurs in murine
tumors and ROS-damaged
phenylalanine,
meta-tyrosine (m-Tyr), was proposed as the serum anti-
tumor factor primarily responsible for CR. Herein, we demonstrate for the first time that CR happens in different experimental human solid
tumors (prostate, lung anaplastic, and
nasopharyngeal carcinoma). Moreover, m-Tyr was detected in the serum of mice bearing
prostate cancer (PCa) xenografts. Primary
tumor growth was inhibited in animals injected with m-Tyr. Further, the CR phenomenon was reversed when secondary implants were injected into mice with
phenylalanine (Phe), a protective
amino acid highly present in primary
tumors. PCa cells exposed to m-Tyr in vitro showed reduced cell viability, downregulated NFκB/STAT3/Notch axis, and induced autophagy; effects reversed by Phe. Strikingly, m-Tyr administration also impaired both, spontaneous
metastasis derived from murine mammary
carcinomas (4T1, C7HI, and LMM3) and PCa experimental
metastases. Altogether, our findings propose m-Tyr delivery as a novel approach to boost the therapeutic efficacy of the current treatment for
metastasis preventing the escape from
tumor dormancy.